SlideShare una empresa de Scribd logo
1 de 27
Dr Dane Horsfall FACEM
    Cabrini Hospital
   Literature extensive
   Listen to this talk!
   Journal watch-http://emergency-medicine.jwatch.org/
   EM:RAP-http://www.emrap.org/
   Landmark Trials -Trials that affect our
    practice
   NINDS 1995/ECASS III 2008
   Rivers 2001/Surviving Sepsis 2008 + Case
   USA vs Canada: NEXUS 2001/Canadian
    Cervical Spine 2001
   SAFE 2004
   Sullivan 2007
   Perry/Steill SAH 2011
   National Institute of Neurological Disorders
    and Stroke-Washington DC
   “t-PA for acute ischemic stroke”
   Randomized, Double Blinded, recombt-PA
    (Alteplase)
   tPA 0.9mg/kg(max 90mg) 10% bolus then inf
    1/24
   Recommended tPA< 3/24
   NIHSS-National Institutes of Health Stroke Scale
    ◦ neuro deficit, 42-point scale, neurologic deficits in 11 categories.
      Eg mild facial paralysis = 1, complete right hemiplegia/aphasia
      =25.
   Barthel Index
    ◦ perform activities of daily living (eating, bathing, walking, toilet)
      out of 100
   Modified Rankin Scale-overall assessment of function
    ◦ 0= asymptomatic up to 5 =severe disability
   Glasgow Outcome Scale-global assessment of function
    ◦   1=good recovery,
    ◦   2=moderate disability
    ◦   3=severe disability
    ◦   4=vegetative state
    ◦   5=death
   Part 1 291pts NIHSS score at 24hrs= no
    difference
   Part 2 333pts Combination score at 3/12
   Results combined for analysis
   t-PA minimal/no disability scores- 12% absolute
    increase, 32% relative, in,   NNT=8
   t-PA Increase ICH by 6%     NNH=17
    ◦ Assoc with more severe isch strokes/more oedema on CT
   Mortality t-PA 17%, Placebo 21% (Not stat.
    significant)
   European Cooperative Acute Stroke Study
   “Thrombolysis with Alteplase 3 to 4.5 Hrs after
    Acute Ischemic Stroke”
   821pts tPA 3-4.5 hrs
   90 day disability –modified Rankin Scale
    ◦ 0-1 no disability t-PA 52% vsPlac 45% - NNT 14
    ◦ 2-6 disability
   ICH(symp) t-PA 2.4% vsPlac 0.2% - NNH 45
   Mortality t-PA 7.7% vsPlac 8.4% no difference
   BUT studies showing no Difference:
    ◦ ECASS I 1995 620pts tPA< 6/24
    ◦ ECASS II 1998 300pts 0-6hrs
   Contraindications:
    ◦ Bleeding risk
      Anticoagulants, Platelets <100
      Massive CVA > 1/3 cerebral hemisphere-obtund/complete
       hemiplegia
      Uncontrolled HT >185/110
      CVA/Head Injury in last 3/12 or ICH at an time
      Bleed in last 3/52, bleeding diathesis, arterial puncture last 7/7
      Pregnancy
      Trauma/Surgery in last 14/7
    ◦ Not Stroke:
      Seizures
      Hypoglycaemia
    ◦ No significant improvement possible
      Resolving stroke
      Previous disability
   263 pts Rx in ED for 6/24 prior to ICU:
    ◦   130 EGDT
    ◦   133 standard Rx
    ◦   In hospital Mortality EGDT 30%, Standard 46%
    ◦   NNT 6
   EGDT:
    ◦ CVP 8-12mmHg if < Fill 500ml bolus N/S every 30
      mins
    ◦ MAP >65mmHg if <vasopressorsNoradrenaline
    ◦ ScvO2 (central mixed venous O2 sat) >70% if <Tx
      RBC to Hct> 30% if ScvO2 still
      <inotropes(dobutamine)
         Central venous Sats>70% surrogate marker of adequate
          tissue perfusion-ie adequate resus from septic shock
   Funded by manufacturer of CVC
   High control mortality
   Dr Rivers managing pts in ED
   Continuous Scv O2sats not practical to
    measure
   Cant argue against concept
   EGDT
   Antibiotic within 1 hr
   Source Control
   crystalloid or colloid fluid resuscitation
   Vasopressor = Noradrenaline
   Dobutamine if CO low post
    filling/vasopressors
   Stress-dose steroid only if BP poorly
    responsive to vasopressors
BIBA at 0430 - fever and severe R leg pain since 0100

PHx
 CLL/Neutropenia - treated with gCSF

0435-
Temp         400C
BP           87/62      mmHg
HR           160/min irregular (AF)
RR           17/min
O2 sat       95% (air)

Right leg red / swollen to thigh “Cellulitis”
Two peripheral IVs,
IV Tazocin            4.5g (early broad spectrum antis✔)
IV fluid              N/saline 1000mls (filling✔)
IV analgesia          Morphine increments
IV Digoxin            500 mcg
   Persistent hypotension, SBP 70-90/DBP 50-60
   Remained in AF
   Pain very difficult to control
   Temp 38.4

   0720-Hypotension persists 80/50
    Rx-Gelofusine 500 and further 1000 ml N/Saline
    (Filling✔)
   0845             IDC
   0900             IV Metaraminol increments
   0930             IV Gelofusine then IV Albumin
   1000             CVC (1000, IJV) CVP 28-30-well filled ✔
   1035             Noradrenalineinf -Vasopressor ✔
   1200             IV Vancomycin 1g
   1220             Transfer ICU

   Non EGDT-central venous sats, Survivng sepsis-
    Source control

   Outcome
    ◦ Clinical Dx Necrotizing Fasciitis by ID, pt palliated
      deceased later that day in ICU
   National Emergency X-ray Utilization Study
    (Jerry Hoffman UCLA)
   34,000pts, 21 sites, prospective observation
    of decision tool: Sens>99% Spec 12%
   If none of 5 clinical signs=clear Cx spine
    ◦   Midline tenderness
    ◦   Distracting injury
    ◦   Altered GCS
    ◦   Neurology
    ◦   Intoxication
   9000pts normal conscious state**
   Sens 100%, spec 45%
   1. High risk factors
    ◦ age>65
    ◦ Mechanism (fall>1m,axial,MCA >100km/hr, motorbike,
      bicycle)
    ◦ Neuro*
   2. Low Risk factors
    ◦ low speed MCA
    ◦ sitting/ walking
    ◦ no midline tenderness*/delayed pain
   3. Able to Laterally neck rotation 45 degrees?
   Advantages
    ◦ Mechanism
    ◦ Age >65
   Disadvantages
    ◦ Complicated
    ◦ No distracting injury*
   A comparison of Albumin and Saline for fluid
    resus in ICU (Saline vsAlbumin Fluid
    Evaluation)
   Multicentre, randomised, double blinded,
    7000pts 4% Alb vs N/Saline 28/7- no
    difference in mortality
   Conclusion- Use N/Saline
   “Early treatment with prednisolone or acyclovir in
    Bell's palsy”
   Double-blind, placebo-control, randomized trial
   500 Pts with Bells (no Herpes vesicles) < 72 hrs
    onset
   10/7 Rx with:
    ◦   Pred 25mg bd
    ◦   Acyclovir
    ◦   Both
    ◦   Placebo
   Rating facial paralysis at 3 and 9/12 with
    “House-Brackmann scale” (1 normal to 6 total
    paralysis)
   Recovery at 3/12
    ◦ Pred 83% vs no Pred 64%
    ◦ Acyclovir 71% vs no Acyclovir 75%
    ◦ Both 80%
   Recovery at 9/12
    ◦ Pred 94% vs no Pred 82%
    ◦ Acyclovir 85% vs no Acyclovir 91%
    ◦ Both 93%
   Conclusion-Give Prednisolone!!!
   Supported by results from: T Berg et al “The Effect of
    Prednisolone on Sequelae in Bell's Palsy” Arch Otolaryngololgy
    - Head Neck Surg. 2012;138(5):445-449 May 2012
   “Sensitivity of CT < 6/24 H/A onset for Dx
    SAH: prospective cohort study”
   3100 pts, 11 Hospitals, 2000-2009
   Adults, New acute h/a, no abNNeuro-?SAH
   240 SAH (8%)
   Overall CT(3rd Gen) 93% sensitive, 100%specific
   Subgroup 950pts CT < 6/24 100%
    sens/specific (Dx all 121 SAH) ie Normal CT
    <6/24 rules oot SAH
   Urgent CT (Cabrini CT ?3rd Gen)
   ?to LP or not to LP – depends on case and
    discussion with patient
   Perry study not validated in Australia-unlikely
    to be repeated
   Some ED’s have changed protocols
   NINDS - “t-PA for acute ischemic stroke”, N Engl J Med
    1995;333:1581-7
   ECASS III – “Thrombolysis with Alteplase 3 to 4.5 Hours after
    Acute Ischemic Stroke” N Eng J Med 2008;359:1317
   Rivers et al – “Early goal-directed therapy in the treatment of
    severe sepsis and septic shock”, N Engl J Med, 345(19):1368-
    77, 2001 Nov 8.
   Surviving Sepsis–Dellinger RP et al. January 2008 "Surviving
    Sepsis Campaign: international guidelines for management of
    severe sepsis and septic shock: 2008". Intensive Care Med 34
    (1): 17–60.
   NEXUS – J Hoffman and The National Emergency X-Ray
    Utilization Study Group – “Validity of a set of clinical criteria
    to rule out injury to the cervical spine in patients with blunt
    trauma”, N Engl J Med 2000;343:94-9
   Stiell IG et al, “The Canadian C-spine rule for radiography in
    alert and stable trauma Patients”, JAMA. 2001 Oct
    17;286(15):1841-8
   SAFE – “A Comparison of Albumin and Saline for Fluid
    Resuscitation in the ICU”, N Engl J Med 2004;350: 2247-56.
   Sullivan et al – “Early treatment with prednisolone or acyclovir
    in Bell's palsy”, N Engl J Med. 2007 Oct 18;357(16):1598-607
   “The Effect of Prednisolone on Sequelae in Bell's Palsy” Arch
    Otolaryngology Head Neck Surg. 2012;138(5):445-449 May
    2012
   Perry/Steill et al – “Sensitivity of CT performed within six
    hours of onset of headache for diagnosis of SAH: prospective
    cohort study” , BMJ 2011 July18;343:d4277

Más contenido relacionado

La actualidad más candente

Newer oral anticoagulant 8.9.16
Newer oral anticoagulant 8.9.16Newer oral anticoagulant 8.9.16
Newer oral anticoagulant 8.9.16DR ANUP PETARE
 
Oral anticoagulation in AF
Oral anticoagulation in AFOral anticoagulation in AF
Oral anticoagulation in AFPavan Rasalkar
 
Fantastic NOACs and how to use them
Fantastic NOACs and how to use themFantastic NOACs and how to use them
Fantastic NOACs and how to use them建豪 陳
 
Cadth 2015 e5 noac ad symposium_panel_14apr2015
Cadth 2015 e5 noac ad symposium_panel_14apr2015Cadth 2015 e5 noac ad symposium_panel_14apr2015
Cadth 2015 e5 noac ad symposium_panel_14apr2015CADTH Symposium
 
Rivaroxaban
RivaroxabanRivaroxaban
Rivaroxabantgraphos
 
Angiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + ValsartanAngiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + ValsartanJai Parekh
 
new oral anticoagulants
new oral anticoagulantsnew oral anticoagulants
new oral anticoagulantsderosaMSKCC
 
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT  Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT hospital
 
Emergency Management of Patients Taking Direct Oral Anticoagulants
Emergency Management of Patients Taking Direct Oral AnticoagulantsEmergency Management of Patients Taking Direct Oral Anticoagulants
Emergency Management of Patients Taking Direct Oral AnticoagulantsUFJaxEMS
 
Overview of Non Vitamin K oral anticoagulants
Overview of  Non Vitamin K oral anticoagulantsOverview of  Non Vitamin K oral anticoagulants
Overview of Non Vitamin K oral anticoagulantsNeeraj Varyani
 
Angiongensin receptor(full permission)
Angiongensin receptor(full permission)Angiongensin receptor(full permission)
Angiongensin receptor(full permission)drucsamal
 
Dabigatran
DabigatranDabigatran
Dabigatranhospital
 

La actualidad más candente (20)

Newer oral anticoagulant 8.9.16
Newer oral anticoagulant 8.9.16Newer oral anticoagulant 8.9.16
Newer oral anticoagulant 8.9.16
 
Oral anticoagulation in AF
Oral anticoagulation in AFOral anticoagulation in AF
Oral anticoagulation in AF
 
Fantastic NOACs and how to use them
Fantastic NOACs and how to use themFantastic NOACs and how to use them
Fantastic NOACs and how to use them
 
xaban anticoagulation
xaban anticoagulationxaban anticoagulation
xaban anticoagulation
 
Cadth 2015 e5 noac ad symposium_panel_14apr2015
Cadth 2015 e5 noac ad symposium_panel_14apr2015Cadth 2015 e5 noac ad symposium_panel_14apr2015
Cadth 2015 e5 noac ad symposium_panel_14apr2015
 
Rivaroxaban
RivaroxabanRivaroxaban
Rivaroxaban
 
Angiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + ValsartanAngiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + Valsartan
 
new oral anticoagulants
new oral anticoagulantsnew oral anticoagulants
new oral anticoagulants
 
newer oral anticoagulents
newer oral anticoagulentsnewer oral anticoagulents
newer oral anticoagulents
 
Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT  Dabigatran guidelines and reversal PPT
Dabigatran guidelines and reversal PPT
 
Emergency Management of Patients Taking Direct Oral Anticoagulants
Emergency Management of Patients Taking Direct Oral AnticoagulantsEmergency Management of Patients Taking Direct Oral Anticoagulants
Emergency Management of Patients Taking Direct Oral Anticoagulants
 
Overview of Non Vitamin K oral anticoagulants
Overview of  Non Vitamin K oral anticoagulantsOverview of  Non Vitamin K oral anticoagulants
Overview of Non Vitamin K oral anticoagulants
 
Angiongensin receptor(full permission)
Angiongensin receptor(full permission)Angiongensin receptor(full permission)
Angiongensin receptor(full permission)
 
NOAC use - brief handout
NOAC use - brief handoutNOAC use - brief handout
NOAC use - brief handout
 
NOACs in the ED
NOACs in the EDNOACs in the ED
NOACs in the ED
 
Rivaroxaban
RivaroxabanRivaroxaban
Rivaroxaban
 
Direct oral anticoagulant
Direct oral anticoagulantDirect oral anticoagulant
Direct oral anticoagulant
 
Jc2
Jc2Jc2
Jc2
 
NOACS
NOACSNOACS
NOACS
 
Dabigatran
DabigatranDabigatran
Dabigatran
 

Destacado

ACEM Fellowship
ACEM FellowshipACEM Fellowship
ACEM Fellowshiptbf413
 
Sore feet
Sore feetSore feet
Sore feettbf413
 
Code pink
Code pinkCode pink
Code pinktbf413
 
Rethinking On-Site Clinics
Rethinking On-Site ClinicsRethinking On-Site Clinics
Rethinking On-Site Clinicsweatrust
 
Case presentation Urosepsis
Case presentation UrosepsisCase presentation Urosepsis
Case presentation Urosepsistbf413
 
Blood bank morgan & jessi
Blood bank morgan & jessiBlood bank morgan & jessi
Blood bank morgan & jessipayneje
 
Aortic dissection
Aortic dissectionAortic dissection
Aortic dissectiontbf413
 
Vertigo
VertigoVertigo
Vertigotbf413
 
Attenuated total reflectance spectroscopy
Attenuated total reflectance spectroscopy Attenuated total reflectance spectroscopy
Attenuated total reflectance spectroscopy Samiksha Sawant
 
3 Pharmacy Trends You Should Know for 2015
3 Pharmacy Trends You Should Know for 20153 Pharmacy Trends You Should Know for 2015
3 Pharmacy Trends You Should Know for 2015weatrust
 
Understanding the slit lamp
Understanding the slit lampUnderstanding the slit lamp
Understanding the slit lamptbf413
 
Medical education 2013
Medical education 2013Medical education 2013
Medical education 2013tbf413
 
ST elevation
ST elevationST elevation
ST elevationtbf413
 
Attenuated total reflectance spectroscopy
Attenuated total reflectance spectroscopyAttenuated total reflectance spectroscopy
Attenuated total reflectance spectroscopychaitanya kolli
 
Emergency Dermatology
Emergency DermatologyEmergency Dermatology
Emergency Dermatologytbf413
 

Destacado (20)

GLAUCOMA
GLAUCOMAGLAUCOMA
GLAUCOMA
 
ACEM Fellowship
ACEM FellowshipACEM Fellowship
ACEM Fellowship
 
Sore feet
Sore feetSore feet
Sore feet
 
Asthma
AsthmaAsthma
Asthma
 
Code pink
Code pinkCode pink
Code pink
 
peptic ulcer
peptic ulcerpeptic ulcer
peptic ulcer
 
Rethinking On-Site Clinics
Rethinking On-Site ClinicsRethinking On-Site Clinics
Rethinking On-Site Clinics
 
Case presentation Urosepsis
Case presentation UrosepsisCase presentation Urosepsis
Case presentation Urosepsis
 
Blood bank morgan & jessi
Blood bank morgan & jessiBlood bank morgan & jessi
Blood bank morgan & jessi
 
Aortic dissection
Aortic dissectionAortic dissection
Aortic dissection
 
Vertigo
VertigoVertigo
Vertigo
 
Rendezvous with ray
Rendezvous with rayRendezvous with ray
Rendezvous with ray
 
Attenuated total reflectance spectroscopy
Attenuated total reflectance spectroscopy Attenuated total reflectance spectroscopy
Attenuated total reflectance spectroscopy
 
NIPV for Peds
NIPV for PedsNIPV for Peds
NIPV for Peds
 
3 Pharmacy Trends You Should Know for 2015
3 Pharmacy Trends You Should Know for 20153 Pharmacy Trends You Should Know for 2015
3 Pharmacy Trends You Should Know for 2015
 
Understanding the slit lamp
Understanding the slit lampUnderstanding the slit lamp
Understanding the slit lamp
 
Medical education 2013
Medical education 2013Medical education 2013
Medical education 2013
 
ST elevation
ST elevationST elevation
ST elevation
 
Attenuated total reflectance spectroscopy
Attenuated total reflectance spectroscopyAttenuated total reflectance spectroscopy
Attenuated total reflectance spectroscopy
 
Emergency Dermatology
Emergency DermatologyEmergency Dermatology
Emergency Dermatology
 

Similar a Emergency medicine research

Stieber - Prevention of Postop AF in CT Surgery (2016)
Stieber - Prevention of Postop AF in CT Surgery (2016)Stieber - Prevention of Postop AF in CT Surgery (2016)
Stieber - Prevention of Postop AF in CT Surgery (2016)Jennifer Stieber, MPH, MS
 
Stroke2013update teleron
Stroke2013update teleronStroke2013update teleron
Stroke2013update teleronpkhohl
 
ACTEP2014: Sepsis management has anything change
ACTEP2014: Sepsis management has anything change ACTEP2014: Sepsis management has anything change
ACTEP2014: Sepsis management has anything change taem
 
STROKE CODE CASE REPORT AND PROTOCOL.pptx
STROKE CODE CASE REPORT AND PROTOCOL.pptxSTROKE CODE CASE REPORT AND PROTOCOL.pptx
STROKE CODE CASE REPORT AND PROTOCOL.pptxkenanga3hsah
 
Hypertension management- Angina IHD
Hypertension management- Angina IHDHypertension management- Angina IHD
Hypertension management- Angina IHDcardiositeindia
 
SCA non-ST+ de la personne âgée - D.U. MUPA 2018
SCA non-ST+ de la personne âgée - D.U. MUPA 2018SCA non-ST+ de la personne âgée - D.U. MUPA 2018
SCA non-ST+ de la personne âgée - D.U. MUPA 2018Nicolas Peschanski, MD, PhD
 
Iv thrombolysis in clinical practicefinal 11082021
Iv thrombolysis in clinical practicefinal 11082021Iv thrombolysis in clinical practicefinal 11082021
Iv thrombolysis in clinical practicefinal 11082021Gillian Gordon Perue
 
Rob Mac Sweeney's FFICM Hot Topics Talk March 2016
Rob Mac Sweeney's FFICM Hot Topics Talk March 2016Rob Mac Sweeney's FFICM Hot Topics Talk March 2016
Rob Mac Sweeney's FFICM Hot Topics Talk March 2016robmacsweeney
 
Optimzing sepsis management
Optimzing sepsis managementOptimzing sepsis management
Optimzing sepsis managementEM OMSB
 
Serelaxin in acute heart failure
Serelaxin in acute heart failureSerelaxin in acute heart failure
Serelaxin in acute heart failuredrucsamal
 
Acute Pulmonary Embolism Overview lecture.ppt
Acute Pulmonary Embolism Overview lecture.pptAcute Pulmonary Embolism Overview lecture.ppt
Acute Pulmonary Embolism Overview lecture.pptBasilQuran
 
TC's emergency medicine wrap up 3
TC's emergency medicine wrap up 3TC's emergency medicine wrap up 3
TC's emergency medicine wrap up 3SCGH ED CME
 
Cardiac Pet Power Point
Cardiac Pet Power PointCardiac Pet Power Point
Cardiac Pet Power PointELITE IMAGING
 
Post cardiac arrest care in ED
Post cardiac arrest care in EDPost cardiac arrest care in ED
Post cardiac arrest care in EDkellyam18
 
Early Goal Directed Therapy in 2015
Early Goal Directed Therapy in 2015Early Goal Directed Therapy in 2015
Early Goal Directed Therapy in 2015Yazan Kherallah
 
Nonclinical Models of Heart Failure - Cardiomyopathy and Pressure Overload
Nonclinical Models of Heart Failure - Cardiomyopathy and Pressure OverloadNonclinical Models of Heart Failure - Cardiomyopathy and Pressure Overload
Nonclinical Models of Heart Failure - Cardiomyopathy and Pressure OverloadCorDynamics
 
Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020EkaPratiwi69
 
Oesophageal Doppler Stroke Volume Optimisation
Oesophageal Doppler Stroke Volume OptimisationOesophageal Doppler Stroke Volume Optimisation
Oesophageal Doppler Stroke Volume Optimisationjavier.fabra
 

Similar a Emergency medicine research (20)

Stieber - Prevention of Postop AF in CT Surgery (2016)
Stieber - Prevention of Postop AF in CT Surgery (2016)Stieber - Prevention of Postop AF in CT Surgery (2016)
Stieber - Prevention of Postop AF in CT Surgery (2016)
 
Stroke2013update teleron
Stroke2013update teleronStroke2013update teleron
Stroke2013update teleron
 
ACTEP2014: Sepsis management has anything change
ACTEP2014: Sepsis management has anything change ACTEP2014: Sepsis management has anything change
ACTEP2014: Sepsis management has anything change
 
STROKE CODE CASE REPORT AND PROTOCOL.pptx
STROKE CODE CASE REPORT AND PROTOCOL.pptxSTROKE CODE CASE REPORT AND PROTOCOL.pptx
STROKE CODE CASE REPORT AND PROTOCOL.pptx
 
Hypertension management- Angina IHD
Hypertension management- Angina IHDHypertension management- Angina IHD
Hypertension management- Angina IHD
 
SCA non-ST+ de la personne âgée - D.U. MUPA 2018
SCA non-ST+ de la personne âgée - D.U. MUPA 2018SCA non-ST+ de la personne âgée - D.U. MUPA 2018
SCA non-ST+ de la personne âgée - D.U. MUPA 2018
 
Iv thrombolysis in clinical practicefinal 11082021
Iv thrombolysis in clinical practicefinal 11082021Iv thrombolysis in clinical practicefinal 11082021
Iv thrombolysis in clinical practicefinal 11082021
 
Rob Mac Sweeney's FFICM Hot Topics Talk March 2016
Rob Mac Sweeney's FFICM Hot Topics Talk March 2016Rob Mac Sweeney's FFICM Hot Topics Talk March 2016
Rob Mac Sweeney's FFICM Hot Topics Talk March 2016
 
Optimzing sepsis management
Optimzing sepsis managementOptimzing sepsis management
Optimzing sepsis management
 
Serelaxin in acute heart failure
Serelaxin in acute heart failureSerelaxin in acute heart failure
Serelaxin in acute heart failure
 
Acute Pulmonary Embolism Overview lecture.ppt
Acute Pulmonary Embolism Overview lecture.pptAcute Pulmonary Embolism Overview lecture.ppt
Acute Pulmonary Embolism Overview lecture.ppt
 
TC's emergency medicine wrap up 3
TC's emergency medicine wrap up 3TC's emergency medicine wrap up 3
TC's emergency medicine wrap up 3
 
Cardiac Pet Power Point
Cardiac Pet Power PointCardiac Pet Power Point
Cardiac Pet Power Point
 
Post cardiac arrest care in ED
Post cardiac arrest care in EDPost cardiac arrest care in ED
Post cardiac arrest care in ED
 
Early Goal Directed Therapy in 2015
Early Goal Directed Therapy in 2015Early Goal Directed Therapy in 2015
Early Goal Directed Therapy in 2015
 
Nonclinical Models of Heart Failure - Cardiomyopathy and Pressure Overload
Nonclinical Models of Heart Failure - Cardiomyopathy and Pressure OverloadNonclinical Models of Heart Failure - Cardiomyopathy and Pressure Overload
Nonclinical Models of Heart Failure - Cardiomyopathy and Pressure Overload
 
Cerebral Edema
Cerebral EdemaCerebral Edema
Cerebral Edema
 
Stroke PPT.pptx
Stroke PPT.pptxStroke PPT.pptx
Stroke PPT.pptx
 
Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020Slide materi webinar 28 juni 2020
Slide materi webinar 28 juni 2020
 
Oesophageal Doppler Stroke Volume Optimisation
Oesophageal Doppler Stroke Volume OptimisationOesophageal Doppler Stroke Volume Optimisation
Oesophageal Doppler Stroke Volume Optimisation
 

Último

world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt downloadAnkitKumar311566
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformKweku Zurek
 
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...saminamagar
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxdrashraf369
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptMumux Mirani
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxbkling
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxDr. Dheeraj Kumar
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!ibtesaam huma
 
Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingArunagarwal328757
 

Último (20)

world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt download
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy Platform
 
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in munirka  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in munirka DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.ppt
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptx
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptx
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!
 
Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, Pricing
 

Emergency medicine research

  • 1. Dr Dane Horsfall FACEM Cabrini Hospital
  • 2. Literature extensive  Listen to this talk!  Journal watch-http://emergency-medicine.jwatch.org/  EM:RAP-http://www.emrap.org/  Landmark Trials -Trials that affect our practice
  • 3. NINDS 1995/ECASS III 2008  Rivers 2001/Surviving Sepsis 2008 + Case  USA vs Canada: NEXUS 2001/Canadian Cervical Spine 2001  SAFE 2004  Sullivan 2007  Perry/Steill SAH 2011
  • 4. National Institute of Neurological Disorders and Stroke-Washington DC  “t-PA for acute ischemic stroke”  Randomized, Double Blinded, recombt-PA (Alteplase)  tPA 0.9mg/kg(max 90mg) 10% bolus then inf 1/24  Recommended tPA< 3/24
  • 5. NIHSS-National Institutes of Health Stroke Scale ◦ neuro deficit, 42-point scale, neurologic deficits in 11 categories. Eg mild facial paralysis = 1, complete right hemiplegia/aphasia =25.  Barthel Index ◦ perform activities of daily living (eating, bathing, walking, toilet) out of 100  Modified Rankin Scale-overall assessment of function ◦ 0= asymptomatic up to 5 =severe disability  Glasgow Outcome Scale-global assessment of function ◦ 1=good recovery, ◦ 2=moderate disability ◦ 3=severe disability ◦ 4=vegetative state ◦ 5=death
  • 6. Part 1 291pts NIHSS score at 24hrs= no difference  Part 2 333pts Combination score at 3/12  Results combined for analysis  t-PA minimal/no disability scores- 12% absolute increase, 32% relative, in, NNT=8  t-PA Increase ICH by 6% NNH=17 ◦ Assoc with more severe isch strokes/more oedema on CT  Mortality t-PA 17%, Placebo 21% (Not stat. significant)
  • 7. European Cooperative Acute Stroke Study  “Thrombolysis with Alteplase 3 to 4.5 Hrs after Acute Ischemic Stroke”  821pts tPA 3-4.5 hrs  90 day disability –modified Rankin Scale ◦ 0-1 no disability t-PA 52% vsPlac 45% - NNT 14 ◦ 2-6 disability  ICH(symp) t-PA 2.4% vsPlac 0.2% - NNH 45  Mortality t-PA 7.7% vsPlac 8.4% no difference  BUT studies showing no Difference: ◦ ECASS I 1995 620pts tPA< 6/24 ◦ ECASS II 1998 300pts 0-6hrs
  • 8. Contraindications: ◦ Bleeding risk  Anticoagulants, Platelets <100  Massive CVA > 1/3 cerebral hemisphere-obtund/complete hemiplegia  Uncontrolled HT >185/110  CVA/Head Injury in last 3/12 or ICH at an time  Bleed in last 3/52, bleeding diathesis, arterial puncture last 7/7  Pregnancy  Trauma/Surgery in last 14/7 ◦ Not Stroke:  Seizures  Hypoglycaemia ◦ No significant improvement possible  Resolving stroke  Previous disability
  • 9. 263 pts Rx in ED for 6/24 prior to ICU: ◦ 130 EGDT ◦ 133 standard Rx ◦ In hospital Mortality EGDT 30%, Standard 46% ◦ NNT 6  EGDT: ◦ CVP 8-12mmHg if < Fill 500ml bolus N/S every 30 mins ◦ MAP >65mmHg if <vasopressorsNoradrenaline ◦ ScvO2 (central mixed venous O2 sat) >70% if <Tx RBC to Hct> 30% if ScvO2 still <inotropes(dobutamine)  Central venous Sats>70% surrogate marker of adequate tissue perfusion-ie adequate resus from septic shock
  • 10.
  • 11. Funded by manufacturer of CVC  High control mortality  Dr Rivers managing pts in ED  Continuous Scv O2sats not practical to measure  Cant argue against concept
  • 12. EGDT  Antibiotic within 1 hr  Source Control  crystalloid or colloid fluid resuscitation  Vasopressor = Noradrenaline  Dobutamine if CO low post filling/vasopressors  Stress-dose steroid only if BP poorly responsive to vasopressors
  • 13. BIBA at 0430 - fever and severe R leg pain since 0100 PHx CLL/Neutropenia - treated with gCSF 0435- Temp 400C BP 87/62 mmHg HR 160/min irregular (AF) RR 17/min O2 sat 95% (air) Right leg red / swollen to thigh “Cellulitis”
  • 14. Two peripheral IVs, IV Tazocin 4.5g (early broad spectrum antis✔) IV fluid N/saline 1000mls (filling✔) IV analgesia Morphine increments IV Digoxin 500 mcg
  • 15. Persistent hypotension, SBP 70-90/DBP 50-60  Remained in AF  Pain very difficult to control  Temp 38.4  0720-Hypotension persists 80/50 Rx-Gelofusine 500 and further 1000 ml N/Saline (Filling✔)
  • 16. 0845 IDC  0900 IV Metaraminol increments  0930 IV Gelofusine then IV Albumin  1000 CVC (1000, IJV) CVP 28-30-well filled ✔  1035 Noradrenalineinf -Vasopressor ✔  1200 IV Vancomycin 1g  1220 Transfer ICU  Non EGDT-central venous sats, Survivng sepsis- Source control  Outcome ◦ Clinical Dx Necrotizing Fasciitis by ID, pt palliated deceased later that day in ICU
  • 17. National Emergency X-ray Utilization Study (Jerry Hoffman UCLA)  34,000pts, 21 sites, prospective observation of decision tool: Sens>99% Spec 12%  If none of 5 clinical signs=clear Cx spine ◦ Midline tenderness ◦ Distracting injury ◦ Altered GCS ◦ Neurology ◦ Intoxication
  • 18. 9000pts normal conscious state**  Sens 100%, spec 45%  1. High risk factors ◦ age>65 ◦ Mechanism (fall>1m,axial,MCA >100km/hr, motorbike, bicycle) ◦ Neuro*  2. Low Risk factors ◦ low speed MCA ◦ sitting/ walking ◦ no midline tenderness*/delayed pain  3. Able to Laterally neck rotation 45 degrees?
  • 19. Advantages ◦ Mechanism ◦ Age >65  Disadvantages ◦ Complicated ◦ No distracting injury*
  • 20.
  • 21. A comparison of Albumin and Saline for fluid resus in ICU (Saline vsAlbumin Fluid Evaluation)  Multicentre, randomised, double blinded, 7000pts 4% Alb vs N/Saline 28/7- no difference in mortality  Conclusion- Use N/Saline
  • 22. “Early treatment with prednisolone or acyclovir in Bell's palsy”  Double-blind, placebo-control, randomized trial  500 Pts with Bells (no Herpes vesicles) < 72 hrs onset  10/7 Rx with: ◦ Pred 25mg bd ◦ Acyclovir ◦ Both ◦ Placebo  Rating facial paralysis at 3 and 9/12 with “House-Brackmann scale” (1 normal to 6 total paralysis)
  • 23. Recovery at 3/12 ◦ Pred 83% vs no Pred 64% ◦ Acyclovir 71% vs no Acyclovir 75% ◦ Both 80%  Recovery at 9/12 ◦ Pred 94% vs no Pred 82% ◦ Acyclovir 85% vs no Acyclovir 91% ◦ Both 93%  Conclusion-Give Prednisolone!!!  Supported by results from: T Berg et al “The Effect of Prednisolone on Sequelae in Bell's Palsy” Arch Otolaryngololgy - Head Neck Surg. 2012;138(5):445-449 May 2012
  • 24. “Sensitivity of CT < 6/24 H/A onset for Dx SAH: prospective cohort study”  3100 pts, 11 Hospitals, 2000-2009  Adults, New acute h/a, no abNNeuro-?SAH  240 SAH (8%)  Overall CT(3rd Gen) 93% sensitive, 100%specific  Subgroup 950pts CT < 6/24 100% sens/specific (Dx all 121 SAH) ie Normal CT <6/24 rules oot SAH
  • 25. Urgent CT (Cabrini CT ?3rd Gen)  ?to LP or not to LP – depends on case and discussion with patient  Perry study not validated in Australia-unlikely to be repeated  Some ED’s have changed protocols
  • 26. NINDS - “t-PA for acute ischemic stroke”, N Engl J Med 1995;333:1581-7  ECASS III – “Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke” N Eng J Med 2008;359:1317  Rivers et al – “Early goal-directed therapy in the treatment of severe sepsis and septic shock”, N Engl J Med, 345(19):1368- 77, 2001 Nov 8.  Surviving Sepsis–Dellinger RP et al. January 2008 "Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008". Intensive Care Med 34 (1): 17–60.  NEXUS – J Hoffman and The National Emergency X-Ray Utilization Study Group – “Validity of a set of clinical criteria to rule out injury to the cervical spine in patients with blunt trauma”, N Engl J Med 2000;343:94-9
  • 27. Stiell IG et al, “The Canadian C-spine rule for radiography in alert and stable trauma Patients”, JAMA. 2001 Oct 17;286(15):1841-8  SAFE – “A Comparison of Albumin and Saline for Fluid Resuscitation in the ICU”, N Engl J Med 2004;350: 2247-56.  Sullivan et al – “Early treatment with prednisolone or acyclovir in Bell's palsy”, N Engl J Med. 2007 Oct 18;357(16):1598-607  “The Effect of Prednisolone on Sequelae in Bell's Palsy” Arch Otolaryngology Head Neck Surg. 2012;138(5):445-449 May 2012  Perry/Steill et al – “Sensitivity of CT performed within six hours of onset of headache for diagnosis of SAH: prospective cohort study” , BMJ 2011 July18;343:d4277